New treatment for severe lung disease-related high blood pressure
Official title: Development of a Novel Hyaluronan Inhibitor for the Treatment of Group 3 Pulmonary Hypertension (PH)
Funded at Halo Biosciences, INC. · NIH-11088776 · Data updated 2026-11-12
This study is testing a new treatment for people with pulmonary hypertension caused by lung disease, aiming to make it easier for them to breathe and go about their daily lives by using a special medication that targets a substance involved in the disease.
Quick facts
| Grant type | Sbir 2 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Halo Biosciences, INC. NIH-funded |
| Lab location | 1 site (Palo Alto, UNITED STATES) |
| Project start | May 15, 2024 |
| Project end | April 30, 2026 |
| Funding year | 2025 |
| Award (this year) | $1,036,071 |
| NIH project number | 5R44HL169052-02 |
| Project ID | NIH-11088776 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are patients diagnosed with Group 3 pulmonary hypertension due to interstitial lung disease.
✕Less likely to help
Patients with pulmonary hypertension not related to interstitial lung disease may not benefit from this research.
What this research studies
This research focuses on developing a new treatment for Group 3 pulmonary hypertension caused by interstitial lung disease (PH-ILD), a condition that severely limits patients' ability to breathe and perform daily activities. The approach involves targeting hyaluronan, a substance that contributes to the disease's progression, using a small molecule inhibitor called 4-MU. By improving the drug's effectiveness and bioavailability, the research aims to provide a more effective therapy for patients suffering from this debilitating condition.
Why it matters
Potential benefit: If successful, this research could lead to a novel treatment that significantly improves the quality of life and survival rates for patients with PH-ILD.
How similar studies have gone: Previous research has shown promising results in animal models using similar approaches to target hyaluronan in pulmonary hypertension.
Where this research is happening
-
Halo Biosciences, INC.
Palo Alto, United States Active
Researchers
- Principal investigator: Paladini, Rudy — Halo Biosciences, INC.
- Study coordinator: Paladini, Rudy
Related research
Other NIH-funded projects on the same topics.
-
Understanding how CD4 T cells fuel schistosomiasis-related lung disease
A study explores how specific immune cells and inflammatory signals in schistosomiasis may contribute to pulmonary hypertension in people affected by the disease.
-
CD4 T Cells, Schistosoma, and Pulmonary Hypertension: Understanding How Immune Cells Drive Disease
A human-health focused study uses a mouse model and human samples to explore how immune cells and inflammation may contribute to a lung blood vessel disease linked to schistosomiasis.
-
CD4 T Cells and Schistosoma-Related Pulmonary Hypertension
A study to understand how specific immune cells behave in a lung complication caused by schistosomiasis, with the goal of finding targets to prevent or treat it.
-
Clinical CT Imaging to identify and subtype pulmonary hypertension in COPD
A new CT imaging approach aims to help doctors detect and classify pulmonary hypertension in people with COPD.
-
Right heart remodeling in pulmonary hypertension
In people with pulmonary hypertension, researchers are studying how the right side of the heart changes and why it fails, with the goal of finding new treatments.
-
TEMPO-PH: How the right heart adapts in pulmonary hypertension over time
A study to build a detailed molecular portrait of why the right side of the heart fails in pulmonary hypertension and how a common heart medicine might help.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.